Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+HR+ breast cancer after trastuzumab-based therapy on patient outcomes

Simple item page
dc.conference.dateMAY 23-24, 2020
dc.conference.titleESMO Breast Cancer Virtual Meeting
dc.contributor.authorMartin Jimenez, M.
dc.contributor.authorGnant, M. I.
dc.contributor.authorEjlertsen, B.
dc.contributor.authorMansi, J. L.
dc.contributor.authorRuiz-Borrego, M.
dc.contributor.authorJakobsen, E. H.
dc.contributor.authorOsborne, C. K.
dc.contributor.authorBirhiray, R.
dc.contributor.authorZhang, B.
dc.contributor.authorWong, A.
dc.contributor.authorMoy, B.
dc.contributor.authorHolmes, F. A.
dc.contributor.authoraffiliation[Martin Jimenez, M.] Hosp Gen Univ Gregorio Maranon, Dept Serv Oncol Med, Madrid, Spain
dc.contributor.authoraffiliation[Gnant, M. I.] Med Univ Wien, Dept Surg, Vienna Gen Hosp AKH, Vienna, Austria
dc.contributor.authoraffiliation[Gnant, M. I.] Med Univ Wien, Comprehens Canc Ctr, Vienna Gen Hosp AKH, Vienna, Austria
dc.contributor.authoraffiliation[Ejlertsen, B.] Univ Copenhagen, Clin Oncol, Rigshosp, Copenhagen, Denmark
dc.contributor.authoraffiliation[Mansi, J. L.] Guys & St Thomas Hosp NHS Trust, Oncol, London, England
dc.contributor.authoraffiliation[Ruiz-Borrego, M.] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Jakobsen, E. H.] Vejle Hosp Sygehus Lillebaelt, Oncol, Vejle Sygehus, Vejle, Denmark
dc.contributor.authoraffiliation[Osborne, C. K.] Texas Oncol, Oncol, Dallas, TX USA
dc.contributor.authoraffiliation[Birhiray, R.] Hematol Oncol Indiana, Oncol, Indianapolis, IN USA
dc.contributor.authoraffiliation[Zhang, B.] PUMA Biotechnol, Stat, San Francisco, CA USA
dc.contributor.authoraffiliation[Wong, A.] PUMA Biotechnol, Clin Sci & Pharmacol, San Francisco, CA USA
dc.contributor.authoraffiliation[Moy, B.] Massachusetts Gen Hosp, Ctr Canc, Med Oncol, Boston, MA USA
dc.contributor.authoraffiliation[Holmes, F. A.] Texas Oncol, Breast Med Oncol, Ft Worth, TX USA
dc.contributor.funderPUMA Biotechnology
dc.date.accessioned2025-01-07T15:31:42Z
dc.date.available2025-01-07T15:31:42Z
dc.date.issued2020-05-01
dc.identifier.doi10.1016/j.annonc.2020.03.023
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420361020/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27209
dc.identifier.wosID538879300074
dc.issue.number2
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS43-S43
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleImpact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+HR+ breast cancer after trastuzumab-based therapy on patient outcomes
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía